ALK and neoplasm: Differently from oncogene drivers, such as EGFR and EML4-ALK, which are associated with high response rates to targeted therapies (1-4), the predictive power of tumor PD-L1 expression should be evaluated on the basis of long-term survival outcomes associated with these treatments.